UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma.

ABSTRACT: Upper tract urothelial carcinoma (UTUC) is a rare malignancy. The standard treatment for localized high-risk disease is radical nephroureterectomy, which confers significant morbidity and is not appropriate for all patients. Patients harboring low-risk, non-invasive disease may be candidates for organ-sparing treatment, which includes endoscopic resection with or without intracavitary drug therapy. Successful administration of intracavitary chemotherapy to the upper tracts is impeded by rapid washout of the agent and short dwell times. This has limited the clinical utility of mitomycin C for treatment of upper tract tumors, despite the successful outcomes observed in low-grade urothelial carcinoma of the bladder. Currently, there is an unmet need for development of a technically feasible a

SUBMITTER: Kokorovic A 

PROVIDER: S-EPMC7339071 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature